Hypothesis

XX cells maintain higher basal NADPH production through dosage‑dependent expression of the X‑linked glucose‑6‑phosphate dehydrogenase (G6PD) gene, which fuels glutathione reductase and enhances GST‑mediated clearance of 4‑hydroxynonenal (HNE) and malondialdehyde (MDA) adducts on mitochondrial proteins. This hormone‑independent mechanism provides a biochemical basis for the observed female longevity advantage independent of gonadal steroids.

Mechanistic Rationale

• G6PD resides on the X chromosome and, although subject to X‑inactivation, a subset of alleles escapes silencing in many tissues, yielding ~1.3‑fold higher mRNA in XX versus XY cells [1].
• NADPH generated by G6PD drives the reduction of oxidized glutathione (GSSG) back to GSH, sustaining the glutathione‑dependent detoxification of lipid‑derived aldehydes by glutathione S‑transferases (GSTs) [2].
• Mitochondrial proteins are primary targets of HNE/MDA adduct accumulation with age, and their modification correlates with loss of enzyme activity in genotypes that show age‑related carbonyl stress [3][4].
• Thus, increased X‑linked G6PD dosage could lower steady‑state HNE/MDA adduct levels by bolstering the GSH‑GST pathway, independent of estrogen or testosterone signaling.

Testable Predictions

1. In gonad‑intact and gonadectomized mice, XX animals will exhibit lower mitochondrial HNE/MDA adduct burden than XY counterparts, regardless of gonadal sex.
2. Genetic reduction of G6PD activity (e.g., heterozygous G6pd knockdown) in XX mice will abolish the adduct difference, bringing XX levels up to those of XY mice.
3. Pharmacological inhibition of G6PD will elevate adduct formation in XX cells to XY levels, whereas overexpression of G6PD in XY cells will reduce adducts toward XX levels.
4. The adduct differences will persist in the Four Core Genotypes model, isolating sex‑chromosome complement from hormonal milieu.

Experimental Approach

• Use the Four Core Genotypes mouse colony (XX females, XX males, XY females, XY males) and perform gonadectomy to eliminate hormonal confounds.
• Isolate mitochondrial fractions from skeletal muscle and liver at 6, 12, and 18 months.
• Quantify HNE‑ and MDA‑protein adducts via immunoblot with adduct‑specific antibodies or LC‑MS/MS.
• Measure G6PD activity and NADPH/GSH ratios in the same samples.
• Manipulate G6PD levels using AAV‑mediated shRNA knockdown or CRISPR activation, and assess consequent changes in adduct load.

Potential Outcomes and Falsifiability

If XX mice show significantly lower adduct levels that normalize upon G6pd reduction, the hypothesis is supported. Conversely, if adduct levels are indistinguishable between sex‑chromosome complements regardless of G6PD activity, or if hormonal manipulation alone accounts for any differences, the hypothesis is falsified. This design directly tests whether an X‑linked metabolic gene confers hormone‑independent resistance to lipid peroxidation damage, thereby moving beyond correlative longevity observations to a mechanistic, experimentally testable claim.